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ABSTRACT
Introduction: ARTOS was an international,
prospective, non-interventional, non-
controlled observational study designed to
determine the effectiveness, safety, and
tolerability of moxifloxacin under daily-life
conditions in patients with complicated skin
and skin structure infections (cSSSIs) treated in
Europe, the Middle East, and Asia–Pacific
region.
Methods: Eligible patients included males and
females who were hospitalized patients or
outpatients requiring antibiotic therapy for
cSSSIs and for whom the treating physician
had elected to begin moxifloxacin therapy in
accordance with its approved indications.
Patients were assessed before therapy and then
at one or two follow-up visits. Effectiveness was
assessed with respect to improvement and
resolution of signs and symptoms of cSSSIs
and safety with respect to the nature and
frequency of adverse events and adverse drug
reactions.
Results: A total of 6,594 patients were enrolled
of whom 5,444 had data available for analysis;
4,692 patients received sequential intravenous/
oral (IV/PO) moxifloxacin and 752 exclusively
IV therapy. A majority of patients were aged
between 40 and 79 years and had one or more
comorbid conditions. Post-surgical wound
infection, skin abscess, and diabetic foot
infection were the cSSSIs most frequently
diagnosed and treated with moxifloxacin, with
almost 90% of infections rated moderate or
severe. Treating physicians chose sequential
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moxifloxacin 400 mg for most patients,
switching from IV to PO after 3–4 days. On
average, treatment was maintained for 10 days.
Treatment with moxifloxacin was associated
with rapid relief in symptoms, with 93.2% of
patients experiencing either complete
resolution of symptoms or improvement at
follow-up. Moxifloxacin was well tolerated
with adverse drug reactions occurring in only
2% of patients.
Conclusions: This study, conducted in a ‘real-
world’ setting, confirms the effectiveness and
safety of moxifloxacin in the treatment of a
wide spectrum of cSSSIs seen in routine clinical
practice.
Keywords: Broad-spectrum antibiotic;




The skin and underlying soft tissues are
frequent sites of bacterial infection and one of
the most common reasons for administering
antibiotic therapy. Skin and skin structure
infections (SSSIs) range from relatively benign,
uncomplicated conditions (e.g., carbuncles,
impetigo) to complicated SSSIs [cSSSIs, e.g.,
major abscesses, traumatic wounds, and
diabetic foot infections (DFI)]. cSSSIs are
generally distinguished from uncomplicated
SSSIs by the need for surgical debridement and
drainage in addition to antibiotic treatment [1].
At their most severe, cSSSIs can include
potentially limb- or life-threatening infections
such as necrotizing fasciitis. Consequently, the
management of cSSSIs is complex with the need
for additional surgery, adequate treatment of
comorbidities, antibiotic therapy, prolonged
hospitalization, and lengthy convalescence [2–
5].
The etiology in most cases is bacterial
prompting for empirical intravenous (IV)
antibiotic therapy against the most likely
causative pathogens [6]. In the most serious
cases, patients may also need fluid resuscitation
and organ support, along with revascularization
or limb amputation if severe ischemia is present
[6]. Underlying conditions such as diabetes,
peripheral vascular disease, chronic venous
insufficiency, and compromised immune
systems may complicate or curb the response
to antibiotic therapy [1, 6]; management of
such conditions must, therefore, be addressed
in the course of treatment.
Both Gram-positive bacteria and Gram-
negative bacteria are implicated in cSSSIs.
Staphylococcus aureus is the most frequently
isolated Gram-positive pathogen and the most
common cause of cSSSIs [4, 7], although b-
hemolytic streptococci are also common and
are often associated with rapidly spreading
infections such as erysipelas or cellulitis [1].
Pseudomonas aeruginosa and Escherichia coli are
the most frequently isolated Gram-negative
bacteria in cSSSIs [7]. Mixed infections are
common, especially in patients with major
abscesses and DFI, where staphylococci,
streptococci, Enterobacteriaceae, and Gram-
negative anaerobes, such as Bacteroides spp.,
may be isolated [8].
The antibiotic recommendations in
guidelines reflect the diverse nature and
etiology of bacterial infections of the skin and
skin structures [1, 9–13]. Where infection is
likely to be polymicrobial (e.g., DFI or infection
of the pelvis and perianal region), broad-
spectrum antibiotic coverage is warranted.
Although beta-lactams have traditionally
been the mainstay of broad-spectrum therapy,
fluoroquinolones with enhanced Gram-positive
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activity are increasingly used as first-line agents
in these cases [14].
Moxifloxacin (Avelox, Bayer Pharma AG,
Leverkusen, Germany) is a broad-spectrum
fluoroquinolone possessing greater in vitro
activity against Gram-positive aerobic
pathogens than earlier fluoroquinolones (e.g.,
ciprofloxacin) and it also has potent activity
against Gram-negative bacteria [15]. Additional
activity against anaerobes makes moxifloxacin
particularly useful for infections of mixed
aerobic and anaerobic etiology [14].
Moxifloxacin achieves good penetration into
muscle, subcutaneous adipose tissue, and
inflammatory blister fluid, suggesting that
adequate tissue concentrations can be achieved
in cSSSIs [15]. Evidence for its clinical efficacy in
cSSSIs has been demonstrated in a series of
randomized, Phase III controlled trials [16–18].
Here we report the results of the Avelox in
Routine Treatment of cSSSIs (ARTOS) study,
which aimed at obtaining data first, on the
characteristics of patients treated with
moxifloxacin in a large cohort of patients
coming from various geographic regions and
second, on the effectiveness, safety, and
tolerability of moxifloxacin under daily life
treatment conditions in patients with cSSSIs.
METHODS
Study Design
ARTOS was an international, prospective, non-
interventional, non-controlled observational
study carried out between 2005 and 2009 in
hospitalized patients or in outpatients under
real-life conditions requiring initial IV antibiotic
therapy for cSSSIs. The study was conducted at
more than 600 investigational sites across
Europe, the Middle East, and Asia–Pacific region.
Study investigators could enroll any patient
with a diagnosis of cSSSI, for whom the treating
physician had decided to begin moxifloxacin
therapy in accordance with its approved
indications and according to local guidelines
before inclusion into, and independent of, the
study. Diagnosis of cSSSI was made at the
discretion of the clinician, and it was assumed
that most clinical conditions would include
skin abscess, post-surgical, or post-traumatic
wound infection, bite wound infection,
erysipelas/cellulitis, or DFI. Lesion size and
level of tissue involvement (epidermis, dermis,
fascia, fat, muscle, and bone) were recorded, as
well as co-morbidities, risk factors, and details
on any surgical intervention.
The study was conducted in accordance with
the guidelines of the European Medicines
Agency [19] as well as applicable laws and
regulations. Where required and before the
start of the study, notification and/or approval
of the protocol was also obtained from the
relevant local competent authorities, ethics
committees and/or institutional review boards
in each country. Patients gave written informed
consent if it was required by local law at the
time of study start before documentation of
effectiveness and safety findings.
Treatment Schedule and Assessments
The study protocol defined that moxifloxacin
should be administered in accordance with the
recommendations prevailing at the time of the
study and specified in the summary of product
characteristics for each country. In Europe, for
example, the recommended dosage and
treatment duration is a once-daily 400 mg IV
infusion of moxifloxacin with a switch to
400 mg per os (PO) at approximately 6 days in
a course lasting from 7 to 21 days [20].
632 Adv Ther (2013) 30:630–643
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For each patient, the treating physician used
a standardized case report form (CRF) to record
data with respect to demographics, pre-
treatment with another antibiotic drug,
concomitant diseases, moxifloxacin treatment,
and adverse events (AEs). Effectiveness and
tolerability were recorded at an initial visit and
one or two follow-up visits, with scheduling
carried out at the discretion of the treating
physician in line with daily routine practice.
Effectiveness assessments included severity of
infection, clinical signs and symptoms,
duration until improvement, duration until
recovery, duration until wound closure, and
overall response to treatment. At the last clinic
visit, physicians were asked to evaluate
moxifloxacin treatment by cSSSI diagnosis,
classifying effectiveness as ‘very good’, ‘good’,
‘sufficient’, or ‘insufficient’. Treating physicians
were also asked to record if they would consider
using moxifloxacin again for another patient.
Safety assessments included overall tolerability
of moxifloxacin together with the frequency of
AEs, their seriousness, and what action was
taken in respect of AEs and their outcome.
Data Analyses
The ARTOS study enrolled a total 6,594
patients, of whom 5,444 had data available for
safety and effectiveness analysis. Analyses, all of
which were descriptive and not subject to
formal statistical testing, were based on the
analyzed population of 5,444 patients. This
included all patients diagnosed with cSSSI and
who had received at least one dose of
moxifloxacin during the observational period.
Of the 467 patients excluded from the analyzed
population, the majority (n = 345) did not have
an established diagnosis of cSSSI. Patients who
received moxifloxacin exclusively orally
(n = 683) were also excluded from the analysis
as initial oral administration of moxifloxacin is
not approved in the label for cSSSIs. Other
reasons for exclusion included retrospective
documentation, in which the initial visit or all
visits had occurred more than 2 days before the
actual start of study or after the official study
end, lack of symptom documentation at the
initial visit, no record of intake or assessment of
response to moxifloxacin, and lost to follow-up.
RESULTS
Patients
Of the 5,444 patients for whom data were used in
the effectiveness and safety analyses, 3,499 were
treated in Europe with the majority (2,019)
treated in Germany. Of the remaining 1,480
patients, 1,017 were treated in the Middle East
(Saudi Arabia, Yemen, and United Arab Emirates)
and the rest in Pakistan (276), the Philippines
(481), Indonesia (102), and Taiwan (69).
Patients’ demographic parameters and their
medical history are summarized in Table 1. More
male patients than females were enrolled; the
mean age was 55.6 ± 17.9 years. Comorbidity was
common amongst the study population, with
3,917 (72.0%) patients having at least one
concurrent disease or disorder. Cardiac and
vascular diseases were the most common
comorbidities, followed by endocrine and
metabolic disorders (Table 1). Among risk factors
known to predispose to cSSSI, diabetes mellitus
was documented most frequently followed by
peripheral vascular disease (Table 1). Consistent
with the presence of any comorbidity [75% of
patients received concomitant therapies, most
frequently for the gastrointestinal tract,
metabolism, and cardiovascular system [e.g.,
insulin was prescribed for 1,037 (19.0%)
patients, acetylsalicylic acid for 677 patients
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(12.4%), and enoxaparin for 568 patients
(10.4%)]. More than a third of patients had
received prior antibiotic therapy for the current
cSSSI, with cephalosporins and penicillins
administered to 929 (17.1%) and 812 (14.9%)
patients, respectively. A higher proportion of
patients in the Asia–Pacific region had received
prior antibiotic therapy compared with those in
the Middle East and Europe (Table 1). Pre-treated
patients tended to have infections of greater
severity in comparison with patients who had
not received prior antibiotic therapy. Across the
three regions, severe disease was reported more
frequently in Europe (47.4%) compared with
38.1% in the Middle East, and 37% in Asia–
Pacific, respectively.
Patients presenting with post-surgical wound
infections accounted for the most frequently
recorded cSSSIs, closely followed by skin
abscesses and DFI (Table 2). Among patients
aged\60 years, skin abscesses (28.0%) and post-
surgical wound infections (22.9%) were the
most common cSSSIs. In patients aged
C60 years, DFI were the most common (28.6%).
Of the 1,103 patients with DFI, 701 (63.6%)
suffered peripheral neuropathy and 614 (55.7%)
peripheral vascular disease. In the 791 (71.7%)
patients for whom hemoglobin A1c (HbA1c)
levels were available, mean values were
increased in both male and female patients
(8.4 ± 2.1).
Most patients had lesions that were\40 cm2
in size, although 22.4% had lesions of between
40.0 and 200 cm2. Lesions of C200 cm2 were
reported in 7.6% of patients. In nearly 90% of
patients, infection involved the dermis, the fat
layer, or bone (Table 2). Signs and symptoms
consistent with cSSSIs were present in most
patients before the start of treatment with
moxifloxacin (Table 3). Based on size of lesion,
level of tissue involvement, and accompanying
signs and symptoms, 4,830 (88.7%) patients
were assessed by the treating physician as
having moderate or severe infections. DFI was
the diagnosis most frequently classed as severe.
Treatment
Of the 5,444 patients, 4,692 (86.2%) received
sequential IV followed by PO moxifloxacin.
This was administered for an average
[mean ± standard deviation (SD)] of
10.6 ± 4.6 days (median 10.0 days) (Table 4).
The IV antibiotic therapy was switched to PO
therapy after an average of 3.4 ± 2.5 days in
these patients (median 3 days). Of the 752
(13.8%) patients who received moxifloxacin
exclusively via the IV route, treatment was
maintained for an average of 7.5 ± 4.2 days
(median 6.0 days). While patients with post-
traumatic wounds, infected ulcers, and DFI
required the longest period of treatment, those
patients with skin abscesses and bite wounds
had the shortest courses of treatment (Table 4).
Independently of the route of administration,
almost all patients received the recommended
daily dose of 400 mg moxifloxacin.
Comparisons across the three geographical
regions showed that the mean duration of
sequential IV/PO treatment was shorter in the
Middle East (9.2 ± 3.5 days) than in either
Europe (10.9 ± 4.6 days) or the Asia–Pacific
countries (11.6 ± 5.0 days), with the switch to
PO treatment occurring earlier there too.
Patients treated in the Middle East were
switched from IV to PO moxifloxacin after an
average of only 1.9 ± 1.7 days’ therapy versus
3.7 ± 2.6 days in Europe and 4.0 ± 2.5 days in
the Asia–Pacific countries.
The majority of patients had surgery in
addition to treatment with moxifloxacin, with
debridement being the most frequent procedure
[n = 2044 patients (37.5%)]. A further 1,367
(25.1%) patients had their lesions drained and
Adv Ther (2013) 30:630–643 635
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813 (14.9%) patients underwent unspecified
surgical procedures. Overall rates of surgical
intervention were similar in the three
geographical regions.
Effectiveness
Treatment with IV/PO moxifloxacin was
associated with high rates of improvement and
recovery as assessed by treating physicians in all
three geographic regions. Across the three
regions, 93.2% of patients had experienced
either complete resolution of symptoms or
improvement at follow-up. The condition in
244 (4.5%) patients remained unchanged at
follow-up, while symptoms had worsened in 36
(0.7%) patients. There were no marked regional
differences in the percentage of patients









Post-surgical wound infection, n (%) 1,356 (24.9) 987 (28.2) 149 (14.7) 220 (23.7)
Skin abscess, n (%) 1,148 (21.1) 538 (15.4) 441 (43.4) 169 (18.2)
Diabetic foot infection, n (%) 1,103 (20.3) 754 (21.5) 125 (12.3) 224 (24.1)
Erysipelas/cellulitis, n (%) 820 (15.1) 550 (15.7) 133 (13.1) 137 (14.8)
Post-traumatic wound infection, n (%) 581 (10.7) 987 (28.2) 77 (7.6) 114 (12.3)
Bite wound infections, n (%) 154 (2.8) 117 (3.3) 13 (1.3) 24 (2.6)
Infected ulcer, n (%) 81 (1.5) 71 (2.0) 4 (0.4) 6 (0.6)
Other infections, n (%) 193 (3.5) 89 (2.5) 70 (6.9) 34 (3.7)
Lesion size
\20.0 cm2, n (%) 2,280 (41.9) 1,370 (39.2) 564 (55.5) 346 (37.3)
20.0–40.0 cm2, n (%) 966 (17.7) 589 (16.8) 167 (16.4) 210 (22.6)
40.0–200.0 cm2, n (%) 1,222 (22.4) 839 (24.0) 130 (12.8) 253 (27.3)
C200.0 cm2, n (%) 415 (7.6) 318 (9.1) 17 (1.7) 80 (8.6)
Deepest tissue involvement
Dermis, n (%) 1,681 (30.9) 1,111 (31.8) 280 (27.5) 290 (31.3)
Fat, n (%) 1,254 (23.0) 804 (23.0) 291 (28.6) 159 (17.1)
Muscle, n (%) 667 (12.3) 434 (12.4) 53 (5.2) 180 (19.4)
Bone, n (%) 490 (9.0) 408 (11.7) 27 (2.7) 55 (5.9)
Surgical procedures
Debridement, n (%) 2,044 (37.5) 1,409 (40.3) 204 (20.1) 268 (28.9)
Drainage, n (%) 1,367 (25.1) 688 (19.7) 411 (40.4) 431 (46.4)
Other, n (%) 813 (14.9) 649 (18.5) 92 (9.0) 72 (7.8)
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experiencing improvement (Europe: 30.0%,
Asia–Pacific: 27.3%, Middle East: 28.4%) or
recovery (Europe: 61.5%, Asia–Pacific: 68.7%,
Middle East: 64.8%) following treatment with
moxifloxacin.
Wound closure was assessed in 3,338 patients
(61.3%) during follow-up. Over a period of
approximately 21 days, wound closure was
documented in 1,575 (47.1%) patients with a
mean duration to closure of 11.2 ± 7.3 days
(median 10.0 days). Patients with DFI
underwent a longer recovery until wound
closure, witha meanduration of 15.7 ± 10.5 days.
In general, treatment with moxifloxacin was
associated with rapid symptom improvement.
Over the course of treatment, erythema had
resolved or improved in 91.9% (4,723/5,140) of
patients, edema in 90.0% (4,306/4,786), local
warmth in 93.0% (4,594/4,941), purulence in
94.2% (3,569/3,787), pressure pain in 90.8%
(4,483/4,939), and fever in 95.3% (3,292/3,455)
of patients. Among the 63.0% of patients who
had an elevated white blood cell count at study
enrolment, 87.9% had experienced a decrease by
end of therapy. Symptomatic improvement was
observed within an average of 4.2 ± 2.6 days of
the start of treatment (median 3.0 days) with
patients having full recovery within an average of
8.6 ± 4.4 days (median 7.0 days). Patients with
Table 3 Signs and symptoms of cSSSIs
Signs and symptoms Analyzed population
N = 5,444
Erythema, n (%) 5,140 (94.4)
Edema, n (%) 4,786 (87.9)
Local warmth, n (%) 4,941 (90.8)
Pressure pain, n (%) 4,939 (90.7)
Purulence, n (%) 3,787 (69.6)




WBC white blood cell; cSSSIs complicated skin and skin
structure infections
* Fever: body temperature C37.5 C; mild: 37.5–38.0 C;
moderate: 38.1–39.0 C; severe: C39.1 C
Table 4 Duration of sequential IV/PO and exclusively IV moxiﬂoxacin treatment in patients with cSSSIs
Diagnosis Mean treatment duration – SD, days (range)
Sequential IV/PO N5 4,680* IV N5 751**
All diagnoses 10.6 ± 4.6 (2.0–58.0) 7.5 ± 4.2 (1.0–42.0)
Post-surgical wound infection 10.2 ± 3.9 (3.0–42.0) 7.0 ± 3.9 (1.0–42.0)
Skin abscess 9.2 ± 3.4 (2.0–35.0) 6.0 ± 3.4 (1.0–25.0)
Diabetic foot infection 12.9 ± 5.9 (2.0–58.0) 8.5 ± 3.9 (1.0–21.0)
Erysipelas/cellulitis 10.6 ± 4.0 (2.0–43.0) 7.5 ± 4.4 (1.0–30.0)
Post-traumatic wound infection 10.6 ± 4.1 (3.0–40.0) 9.2 ± 5.2 (1.0–30.0)
Bite wound infections 9.2 ± 3.5 (2.0–22.0) 7.5 ± 3.4 (2.0–14.0)
Infected ulcer 11.1 ± 4.7 (5.0–31.0) 9.4 ± 5.3 (1.0–18.0)
Other infections 10.5 ± 5.6 (3.0–40.0) 6.6 ± 4.1 (1.0–20.0)
IV Intravenous, PO per os, cSSSIs complicated skin and skin structure infections
* Data missing for 12 patients
** Data missing for 1 patient
Adv Ther (2013) 30:630–643 637
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DFI took longer than all other patients to recover
(mean 10.6 ± 5.8 days), while disease severity,
older age, and depth of tissue involvement also
delayed time to recovery. Analysis by region
showed that recovery occurred most rapidly in
patients in the Middle East (mean 7.3 ± 3.8 days)
followed by those in Europe (mean 8.7 ± 4.3
days) and Asia–Pacific (mean 9.5 ± 5.1 days).
A responder versus non-responder
retrospective analysis has shown that
concomitant diseases were more frequent in
patients who did not respond to therapy
(n = 179). Thus, the frequency in this group of
patients was higher for peripheral neuropathy
(17.6 vs 35.2%), peripheral vascular disease (22.5
vs 54.2%), presence of chronic ulceration (7.8 vs
22.9%), and diabetes mellitus (31.0 vs 55.9%)
respectively.
Overall, treating physicians rated
moxifloxacin as ‘very good’ or ‘good’ in 4,950
(90.9%) of the 5444 patients with effectiveness
ratings ranging from 82.6% for DFI to 96.1% for
bite wound infections (Table 5). In general,
effectiveness ratings were higher for younger
patients than for older ones and for those with
mild and moderate infections in comparison
with those with severe infections.
Safety and Tolerability
AEs were documented in 144 patients (2.6%),
with 110 (2.0%) of these identified as adverse
drug reactions (ADRs). Serious AEs were
documented in 0.5% and serious ADRs in
\0.2% of patients (Table 6). AEs led to
permanent discontinuation of treatment in 55
patients, which was attributed to an ADR in 46
Table 5 Physicians’ overall assessment of the effectiveness
of moxiﬂoxacin in complicated skin and skin structure
infections








67.4 24.6 5.6 2.4
Skin abscess 69.6 24.9 2.9 1.9
Diabetic foot
infection
50.9 31.7 9.9 7.1
Erysipelas/
cellulitis




67.3 26.7 4.5 1.4
Bite wound
infections
67.5 28.6 3.2 0.6
Infected ulcer 50.6 35.8 9.9 2.5
Other
infections
60.1 24.9 7.8 6.7
Table 6 Incidence of treatment-emergent AEs among
patients with cSSSIs treated with moxiﬂoxacin
Adverse events (AE) Patients,
n (%)
All AEs 144 (2.6)
ADRs 110 (2.0)
Serious AEs 27 (0.5)
Serious ADRs* 8 (\0.2)
Permanent discontinuation of therapy
due to AE
55 (1.0)
AEs with fatal outcome 13 (0.2)
ADRs with fatal outcome 2 (\0.1)
Total number of patients included was 5,444
ADRs Adverse drug reactions, cSSSIs complicated skin and
skin structure infections
* Infection-related events occurred in three patients,
gastrointestinal disorders in two patients, and
administration site conditions in two patients. Other
serious ADRs included hypersensitivity reactions,
dehydration, headache, acute renal failure, pruritis, and
rash
638 Adv Ther (2013) 30:630–643
123
patients. A total of 13 deaths occurred during
the observation period, two of which were drug-
related; both of these deaths occurred in elderly
patients with DFI and significant comorbidity.
One patient died from sepsis due to infection
with methicillin-resistant S. aureus (MRSA) and
the second from complications arising from
toxic megacolon.
Gastrointestinal events were the most
frequent ADRs occurring during treatment with
moxifloxacin, with diarrhea and nausea affecting
27 (0.5%) and 21 (0.39%) patients, respectively.
Adverse central nervous system events such as
headache and dizziness were the next most
frequent, affecting 10 (0.18%) and 8 (0.15%)
patients, respectively. In the majority of patients
these ADRs had either resolved or improved by
the end of the observation period.
DISCUSSION
ARTOS was an international, prospective, non-
interventional, non-controlled observational
cohort study in patients with cSSSIs.
Observational studies differ from randomized
controlled trials (RCTs) in that a RCT can study
the effect of a new intervention on pre-defined
parameters in a random sample of well-selected
study subjects, whereas observational studies
simply observe the effect of the treatment on a
broader population [21]. Consequently, RCTs are
considered the gold standard for determining
causality between the intervention and clinical
efficacy. Observational studies can still provide
valuable information relevant to real-world
settings about the use of a medication in
routine clinical practice (e.g., characteristics of
patients who receive this medication) and also in
countries which in general are not involved in
clinical development programs (e.g., the Middle
East). In addition, these Phase IV studies are
requested by regulatory authorities [22]. In the
ARTOS study, for example, patients had
participated who would not ordinarily have
been enrolled in a randomized controlled trial
because of significant comorbidity, and the
extent and nature of their cSSSIs (e.g., patients
with necrotizing fasciitis).
In this study, the most frequently diagnosed
cSSSIs were post-surgical wound infections, skin
abscesses, and DFI. When considering the new
Food and Drug Administration diagnostic
criteria applied for enrollment into acute
bacterial skin and skin structure infection
clinical studies [23], many of the patients
enrolled into the ARTOS study had signs and
symptoms of a severe infection. Thus, almost
half of the erysipelas patients had erythema,
edema, and induration of C75 cm2 (and a
systemic sign such as fever C38 C).
Furthermore, approximately 70% of patients
with a wound infection had purulent discharge,
erythema, edema, and an induration of
C75 cm2 with systemic sign, such as fever
C38 C. Frequencies varied between regions,
with skin abscesses notably prevalent among
patients in the Middle East. Peripheral
neuropathy (*65%) and peripheral vascular
disease (*55%) affected almost two-thirds and
more than a half of all patients with DFI, and
osteomyelitis was present in nearly 30% of these
patients. The ARTOS study also revealed that
diabetes was often poorly controlled or
managed as both HbA1c values and fasting
blood glucose levels were higher than the
respective target values (e.g., 6.5% and 7 mM,
respectively) in [60% of these patients.
The increased susceptibility to more severe
infections among patients with significant
comorbidities (e.g., diabetes) or elderly
patients is reflected in this study population,
who were also likely to receive a prior course of
antibiotic (approximately 40% of patients) for
Adv Ther (2013) 30:630–643 639
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their current cSSSI before moxifloxacin
treatment. This suggests that many patients
seen in routine clinical practice have difficult-
to-treat cSSSIs. A higher proportion of elderly
patients enrolled in Europe had severe cSSSIs
than of those in the Middle East and Asia–
Pacific region.
When comorbidities were taken into account
regarding DFI patients, which may influence
the length of therapy and clinical outcome, we
have observed a similar result to that for the DFI
patients enrolled in the RELIEF trial which was a
randomized, double-blind study [18, 24]. Thus,
comparing patients enrolled in the RELIEF and
ARTOS studies regarding specific comorbidities
of DFI patients, the proportion of patients with
peripheral vascular disease ([65.5 vs 55.7%,
respectively), peripheral neuropathy (49.5 vs
63.5%, respectively), or osteomyelitis (20 vs
28.8%, respectively) were rather similar.
Results from the ARTOS study have shown
that moxifloxacin was an effective treatment for
patients, including those with DFI which is one
of the most refractory infections to antibiotic
therapy. A total of 93% of patients experienced
either a complete resolution or an improvement
in their symptoms, with symptomatic
improvement seen rapidly in a matter of a few
days. Patients treated in the Middle East
experienced the shortest time to recovery,
which may be due to the higher frequency of
more easily treatable cSSSIs (e.g., skin abscesses).
DFI was the most frequent diagnosis in the
Asia–Pacific region and patients there had
longer response times in comparison with the
other regions. Data from randomized clinical
trials have shown that moxifloxacin achieves
clinical cure in 79–82% of patients with cSSSIs
[16–18, 24], rates that are comparable with the
results obtained in the ARTOS study. As
mentioned above, the majority of investigators
in the ARTOS study have rated the overall
effectiveness of moxifloxacin as ‘very good’ or
‘good.’ Based on the type of diagnosis it was
found ‘very good’ or ‘good’ in 82.6% of DFI and
86.4% of infected ulcer patients, while the
effectiveness was rated similarly for a higher
proportion of patients with abscesses (94.5%) or
wound infections (92–96.1%).
Across the three geographical regions, the
majority of the patients were treated with
sequential IV/PO moxifloxacin 400 mg,
switching them from IV to PO therapy after an
average of 3–4 days. On average, sequential
therapy was administered for about 10 days.
However, treatment durations of 14 days is
required commonly [24, 25].
Consistent with the results from the earlier
trials, moxifloxacin was generally well tolerated
by patients in this study. In fact, the frequency
of AEs, ADRs, and deaths was lower in the
ARTOS study than those reported in the RCTs,
as were rates of permanent discontinuation of
therapy. A unique feature of large, non-
interventional studies is that they allow for
the identification of rare safety events that
would not be seen in smaller patient
populations in RCTs. In this respect, no
unexpected safety events were seen in the
ARTOS study. The nature of AEs, including
serious AEs, was consistent with the established
safety profile of moxifloxacin as described
recently [26].
Observational studies, in addition to the
strengths as described earlier, also have a
number of limitations. For example, in the
ARTOS study the lack of centralized diagnostic
criteria or stratification by disease severity was
one of the limitations. Interpretation and
analysis of observational studies is somewhat
difficult due to the heterogeneity of patients in
real-life settings. Other limitations were the lack
of active comparator and microbiological data;
thus, effectiveness in relation to microbiological
640 Adv Ther (2013) 30:630–643
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eradication was impossible to ascertain. Indeed,
undertaking microbiological analysis is not
feasible in observational studies involving
several thousand patients. Reliable data
collection on microbiological patterns would
have required the use of specific sampling
methods excluding swabbing, which cannot
be requested in non-interventional studies.
Furthermore, even if information on species is
available, susceptibility varies between regions
and methodological differences could
complicate the analysis. The bacterial etiology
of cSSSIs is well known [1, 4, 15]. Moxifloxacin,
a broad-spectrum antibiotic, has activity against
the most prevalent pathogens such as
methicillin-susceptible S. aureus, E. coli,
Bacteroides spp. It has limited activity against
MRSA and, therefore, moxifloxacin is not the
appropriate option for the treatment of cSSSI
caused by this pathogen. The conclusions of
this study do not probably apply to regions
where MRSA-caused infections are predominant
[27]. In the absence of bacteriological results,
diagnosis of cSSSI and choice of therapy in the
current study were based on the clinician’s
routine practice reflecting available local cSSSI
guidelines [10, 13, 28]. Hence, empirical
antibiotic therapy must be supported by
accurate knowledge of the epidemiology and
resistance patterns when treating infections
that may be caused by multiple pathogens
including resistant microorganisms. Information
on the origin of the infection (i.e., community- vs
hospital-acquired) was not documented in the
present study; however, it is expected that, like in
the previous cSSSI clinical trials conducted with
moxifloxacin, the vast majority of patients had
their wound infection acquired in the
community and they were hospitalized at the
study start to receive initial IV therapy. To mimic
clinical practice, no strict rules were applied for
AE reporting in the investigational sites—except
for serious AEs, which legally had to be
systematically notified by the investigators—and
actual reporting was based on the investigators
medical judgment. This could have created
differences between physicians.
CONCLUSION
In conclusion, the ARTOS study has highlighted
the characteristics of cSSSIs associated with the
use of moxifloxacin in routine clinical practice,
globally and in different regions of the world. In
general, moxifloxacin was used according to
clinical practice guidelines even in the absence
of exact microbiological data. The study also
confirms the effectiveness and tolerability of
this antibiotic for patients with a range of cSSSIs
when used in accordance with the approved
summary of product characteristics [20] and
appropriate local guidelines.
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